Author’s response to reviews

Title: Understanding Side Effects of Therapy for Myasthenia Gravis and their Impact on Daily Life

Authors:

Elizabeth Bacci (elizabeth.bacci@evidera.com)
Karin Coyne (karin.coyne@evidera.com)
Jiat Ling-Poon (poon_jiat_ling@lilly.com)
Linda Harris (linda.harris@alexion.com)
Audra Boscoe (audra.boscoe@gmail.com)

Version: 3 Date: 11 Dec 2019

Author’s response to reviews:

December 11, 2019

Re: Manuscript ID NURL-D-19-00085R2

To Whom It May Concern:

We have revised the manuscript, “Understanding Side Effects of Therapy for Myasthenia Gravis and their Impact on Daily Life,” based on the feedback from the editorial team. Below are our responses to each of the comments.

Editor Comments

- In the Ethics approval and consent to participate subsection please provide an explicit statement so as to say whether or not your study was directly accepted by your local ethics committee.
- Furthermore, please provide the full unabbreviated name of the ethics committee which assessed your study protocol and include a review reference number if possible.
- This study was directly accepted by the local ethics committee and the corresponding statement has been clarified. The ethics committee name and reference number are also included.
In your Ethics approval section, please clarify whether consent obtained from participants was written or verbal. If consent was obtained verbally please include reasoning for this and state if an IRB approved this method of obtaining consent.

This section has been clarified, as written consent was provided by Phase I participants and electronic consent was obtained from Phase II participants.

Please note that the Consent for publication statement refers to consent obtained to include any individual person’s data in any form (including individual details, images or videos). Therefore, please state "Not applicable" in this section as no personal information is provided in your manuscript. The statement regarding authors’ approval of the final manuscript should instead be included in the Authors’ contributions section of the Declarations.

We have revised as suggested above; a statement of author’s contributions is already in the Declarations section.

Please note that in accordance with BMC submission guidelines, we do not allow the use of footnotes. Please instead consider repurposing the footnote found on page 7 as an Endnote which can be presented after the references section.

We have removed the footnote and moved the text to follow the references section.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce any copyrighted materials referenced in their manuscript. Do you have a licence and permission to reference the MMAS-8 from its copyright holder? Since the material contained in the MMAS-8 is copywritten we must ask that you remove all presentation of MMAS-8 content from your manuscript (i.e. (“How often do you have difficulty remembering to take all your medications?”) found on page 7 under the MMAS-8 subheading

Yes, we obtained a license and permission to use the MMAS-8 from the copyright holder. We have removed the exact MMAS-8 item content from the manuscript and summarized the item content in it’s place.